Somerville, MA, United States of America

Mark L Behnke

This inventor holds 28 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 2 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Infinity Pharmaceuticals, Inc., Wyeth, Millennium Pharmaceuticals Limited. Active years: 2000-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Mark L Behnke. Retrieved from https://idiyas.com/inventor/mark-l-behnke

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 28 (Patent Applications = 3)

% Patents Active = 64.3

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 6)

Average Co-Inventor Count = 7.6

ph-index = 12

Forward Citations = 440(Granted Patents)

Location History:

Sommerville, MA (US) (2003 - 2010)
Cambridge, MA (US) (2016)
Somerville, MA (US) (2000 - 2021)

Company Filing History:

16 out of 108

Infinity Pharmaceuticals, Inc.

Millennium Pharmaceuticals Limited

patents

Years Active: 2000-2021

Loading Chart...

Areas of Expertise:

Cyclopamine Analogs

Fatty Acid Amide Hydrolase

Isoxazolines

Cytosolic Phospholipase A2

Asthmatic Conditions

Arthritic Disorders

Clasto-Lactacystin

N-Benzhydryl Indole Compounds

Aldehyde Synthesis

Beta-Lactone

Inhibitors

Analogs

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11007181 - Cyclopamine analogs (2021-05-18),

2. 10406139 - Cyclopamine analogs (2019-09-10),

3. 9951083 - Cyclopamine analogs (2018-04-24),

4. 9492435 - Cyclopamine analogs (2016-11-15),

5. 9149465 - Isoxazolines as inhibitors of fatty acid amide hydrolase (2015-10-06),

6. 9108989 - Inhibitors of fatty acid amide hydrolase (2015-08-18),

7. 8957049 - Inhibitors of fatty acid amide hydrolase (2015-02-17),

8. 8927551 - Isoxazolines as inhibitors of fatty acid amide hydrolase (2015-01-06),

9. 8785635 - Cyclopamine analogs (2014-07-22),

10. 8765735 - Isoxazolines as inhibitors of fatty acid amide hydrolase (2014-07-01),

11. 8669365 - Cyclopamine analogs (2014-03-11),

12. 8629125 - Inhibitors of fatty acid amide hydrolase (2014-01-14),

13. 8349814 - Inhibitors of fatty acid amide hydrolase (2013-01-08),

14. 8329675 - Inhibitors of fatty acid amide hydrolase (2012-12-11),

15. 7947663 - Inhibitors of fatty acid amide hydrolase (2011-05-24),

Title: Profile of Mark L Behnke: Innovator in Pharmaceuticals

Introduction

Mark L Behnke is a prominent inventor based in Somerville, MA, known for his significant contributions to the field of pharmaceuticals. With an impressive portfolio of 28 patents, Behnke has focused his work on developing innovative compounds that have the potential to advance medical treatments.

Latest Patents

Among his latest contributions to the field, Mark L Behnke has created derivatives of cyclopamine, detailed in his patent titled "Cyclopamine analogs." This invention explores novel formulas for these compounds, demonstrating Behnke's commitment to enhancing the efficacy of medicinal products.

Career Highlights

Throughout his career, Behnke has worked with renowned companies, including Infinity Pharmaceuticals, Inc. and Wyeth, where he honed his skills and applied his innovative thinking to tackle complex pharmaceutical challenges. His experience in these companies has greatly influenced his research and patent development.

Collaborations

Mark has collaborated with notable professionals in the industry, including Alfredo C Castro and Michael J Grogan. These partnerships have contributed to the success of his inventions and have helped in the exploration of new therapeutic avenues.

Conclusion

Mark L Behnke stands out as a dedicated inventor in the pharmaceutical industry. His work on cyclopamine analogs and his collaborations with esteemed colleagues highlight his innovative spirit and commitment to advancing healthcare solutions. As he continues to evolve his research, there’s likely more to come from this prolific inventor.

Profile summary based on public USPTO records.